Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Diagnosis of Acute Rejection in Renal Transplant Patients by Urine Mass Spectrometry

9. august 2017 oppdatert av: Wilfried Gwinner, Hannover Medical School

Non-invasive Diagnosis of Acute Rejection in Renal Transplant Patients Using Mass Spectrometry of Urine Samples - a Multicentre Diagnostic Phase III Trial

Reliable and timely detection of acute rejections in renal transplant patients is important to preserve the graft function and to prevent premature graft failure. The current gold standard for the rejection diagnosis is a renal biopsy which is usually performed upon an unexplained decline in the graft function (determined by serum creatinine or clearance). Because of the insensitivity of creatinine determinations and the invasiveness of renal biopsies, non-invasive tests have been suggested to diagnose acute rejection including mass spectrometry (MS) analysis of urine samples.

The ability of MS analysis to detect acute rejection has been demonstrated in small studies on selected patients but evidence is lacking that this test is efficacious in the routine setting of the post-transplant patient care. Based on our previous work that established urine peptide sets for acute rejection by MS, a prospective, multicentre diagnostic phase III study will be executed.

The aim of the study is to prove that this test is as equally effective as the allograft biopsy to detect acute rejection in patients that undergo a biopsy for unexplained renal dysfunction. The perspective of this approach is that the test could be used either in place of the biopsy or as decision guidance whether a biopsy is necessary to confirm the presence of rejection. Another perspective is that the MS test (respectively, a simplified test system derived from this method) could be used in the regular post-transplant surveillance for acute rejection, in place of the relatively insensitive procedure with periodic monitoring of the graft function by creatinine determinations.

Studieoversikt

Status

Fullført

Forhold

Avvisning av nyretransplantasjon

Studietype

Observasjonsmessig

Registrering (Faktiske)

600

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

Tyskland
- - Aachen, Tyskland, 52074
    - RTW University of Aachen
  - Berlin, Tyskland, 10117
    - Charité Universitätsmedizin Berlin
  - Erlangen, Tyskland, 90154
    - University of Erlangen-Nuremberg
  - Essen, Tyskland, 45147
    - Universitätsklinikum Essen
  - Hannover, Tyskland, 30625
    - Hannover Medical School
  - Jena, Tyskland, 07747
    - Universitatsklinikum Jena
  - Köln, Tyskland, 51109
    - Kliniken der Stadt Koln gGmbH
  - München, Tyskland, 81377
    - Ludwig-Maximilians-Universitätsklinik München

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Sannsynlighetsprøve

Studiepopulasjon

Patients with a kidney or combined kidney/pancreas transplantation from several German transplant centres with an acute unexplained allograft dysfunction within the first year of transplantation who require a clinically indicated allograft biopsy

Beskrivelse

Inclusion Criteria:

Adult patients with a kidney or combined kidney/pancreas transplantation
Unexplained renal allograft dysfunction within the first year of transplantation
Renal allograft biopsy, which is clinically indicated to verify or exclude an acute rejection

Exclusion Criteria:

Lacking consent of the patient to participate in the study

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

Hva måler studien?

Primære resultatmål

Resultatmål	Tiltaksbeskrivelse	Tidsramme
Ability of the urine mass spectrometry test to diagnose acute renal allograft rejection, compared to the gold standard 'allograft biopsy' Tidsramme: Results of the urine test will be assessed in relation to the simultaneously performed allograft biopsy (1 day)	In patients with unexplained renal allograft dysfunction who get an allograft biopsy to clarify if an acute rejection is present, a simultaneous urine sample will be taken. The peptide pattern of this urine sample is analyzed by mass spectrometry and a diagnosis is made (rejection present/not present) based on a pre-defined peptide pattern which was established to detect acute allograft rejection. In the primary outcome analysis, the sensitivity and specificity of the rejection diagnosis by the urine test is compared to the diagnosis made by the allograft biopsy.	Results of the urine test will be assessed in relation to the simultaneously performed allograft biopsy (1 day)

Sekundære resultatmål

Resultatmål	Tiltaksbeskrivelse	Tidsramme
Sensitivity and specificity of the urine test to diagnose acute renal allograft rejection in subgroups with different severity grades of the rejection Tidsramme: Results of the urine test will be assessed in relation to the simultaneously performed allograft biopsy (1 day)	Sensitivity/specificity measures for the urine test will be determined in subgroups of patients with different severity of the rejection. Severity grading is based on the pathomorphological classification of the rejection (according to the BANFF classification) and on the functional impairment of the allograft at the time of rejection diagnosis.	Results of the urine test will be assessed in relation to the simultaneously performed allograft biopsy (1 day)
Sensitivity and specificity of the urine test to diagnose acute renal allograft rejection in subgroups with kidney transplantation alone and with combined pancreas/kidney transplantation Tidsramme: Results of the urine test will be assessed in relation to the simultaneously performed allograft biopsy (1 day)	Sensitivity/specificity measures for the urine test will be determined in subgroups of patients who have a kidney transplant or a combined pancreas/kidney transplant.	Results of the urine test will be assessed in relation to the simultaneously performed allograft biopsy (1 day)
Sensitivity and specificity of the urine test to diagnose acute renal allograft rejection in subgroups with concurrent infection Tidsramme: Results of the urine test will be assessed in relation to the simultaneously performed allograft biopsy (1 day)	Sensitivity/specificity measures for the urine test will be determined in subgroups of patients who have concurrent infections at the time of the biopsy and urine sampling such as cytomegaly virus, polyoma virus, and urinary tract infection. The analysis intends to identify potential interference of these conditions with the urine mass spectrometry test.	Results of the urine test will be assessed in relation to the simultaneously performed allograft biopsy (1 day)

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Hannover Medical School

Etterforskere

Hovedetterforsker: Wilfried Gwinner, Prof. /MD, Hannover Medical School

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Generelle publikasjoner

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart

1. oktober 2011

Primær fullføring (Faktiske)

1. mars 2017

Studiet fullført (Faktiske)

15. juni 2017

Datoer for studieregistrering

Først innsendt

14. mars 2011

Først innsendt som oppfylte QC-kriteriene